🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer

RecruitingNAAges 18 Years - anyFemaleFudan University
NCT06911528 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Sentinel Lymph Node Biopsy (SLNB) is a common surgical treatment for breast cancer and a primary method for assessing the pathological status of axillary lymph nodes. Precise intraoperative detection of sentinel lymph nodes during surgery assists in timely evaluation of axillary lymph node pathology and helps in formulating further treatment strategies. Touch imprint cytology (TIC) is one of the most commonly used intraoperative detection techniques. The new intraoperative cellular detection technology, EndoScell Scanner (ES), uses an improved real-time miniaturized fluorescence microscopy system for image acquisition. The ultra-high-resolution images obtained can reach the cellular level. In previous studies, the accuracy and sensitivity of this technology for intraoperative detection of sentinel lymph nodes were comparable to imprint cytology, but it is much more rapid. The detection

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18 years and older (inclusive) * Female * Preoperative pathology confirmed invasive breast carcinoma or ductal carcinoma in situ * Scheduled for sentinel lymph node biopsy * Capable of and willing to provide informed consent Exclusion Criteria: * Patients with a confirmed allergy to methylene blue or sodium citrate tracers * Pregnant or lactating women * Patients unwilling to participate in the clinical study
💊

What it tests

  • EndoScell Scaner (ES) novel intraoperative cellular probing technology
📍

Where

1 site
Fudan University Shanghai Cancer Center
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy